AMLX:NASDAQ
Amylyx Pharmaceuticals Inc
$33.96
arrow_downward
-1.54%(-0.53) 1D
$33.94
arrow_downward
-0.06% (-0.020)todayPre-market
Closed: Sep 3, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AMLX...
Open
$34.49
High
$35.31
Low
$33.73
Mkt. cap
4.26B
Avg. vol.
3.34M
Volume
1.79K
52-wk high
$41.13
52-wk low
$9.71
EPS
-$1.43
Beta
-0.13
Shares outstanding
125.51M
No. of employees
136
Open
$34.49
High
$35.31
Low
$33.73
Mkt. cap
4.26B
Avg. vol.
3.34M
Volume
1.79K
52-wk high
$41.13
52-wk low
$9.71
EPS
-$1.43
Beta
-0.13
Shares outstanding
125.51M
No. of employees
136
News stories
From web sources and news partners
The Globe and Mail
·
2 days ago
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Simply Wall Street
·
3 days ago
Is Amylyx Pharmaceuticals (AMLX) Expensive As Phase 3 Avexitide Data Clears The Way?
Profile
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
About Amylyx Pharmaceuticals Inc